Clinical Trial: A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07623200) titled 'A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia' on May 29.

Brief Summary: This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Essential Thrombocythemia

Intervention: DRUG: INCA033989

Administered intravenous (IV) in accordance with the protocol-defined requirements.

DRUG: Best Available Treatment

Best Available Therapy (BAT) will be selected by the investigator...